SCHEMBL26666325

SCHEMBL26666325

CCOC(=O)C(=O)CC(=O)c1cc(C)ccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.52
PTGER1 P34995 2/20 0.48
PTGER4 P35408 2/20 0.48
PTGER3 P43115 2/20 0.48
PTGER2 P43116 2/20 0.48
NR1H4 Q96RI1 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MRGPRX4 Q96LA9 3/20 0.46
FFAR4 Q5NUL3 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
FOLH1 Q04609 1/20 0.44
SMPD1 P17405 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27188479 0.88 PTGER1 (0.52) LRRK2PTGER1MRGPRX4
SCHEMBL27188704 0.88 LRRK2 (0.50) LRRK2NR1H4ALDH1A1MRGPRX4FFAR4
SCHEMBL6820830 0.88 MRGPRX4 (0.46) LRRK2PTGER1PTGER4PTGER3PTGER2
SCHEMBL69725 0.88 SGMS2 (0.52) PTGER1NR1H4ALDH1A1NPC1MAPT
SCHEMBL30535266 0.88 SGMS2 (0.52) PTGER1NR1H4ALDH1A1NPC1MAPT
SCHEMBL38657361 0.85 LRRK2 (0.53) LRRK2PTGER1PTGER4PTGER3PTGER2
SCHEMBL2944769 0.84 ALDH1A1 (0.47) LRRK2NR1H4ALDH1A1FFAR4SMN1; SMN2
SCHEMBL3956579 0.84 ALDH1A1 (0.47) NR1H4ALDH1A1MRGPRX4FFAR4SMN1; SMN2
SCHEMBL7911106 0.83 ALDH1A1 (0.55) NR1H4ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL12939113 0.83 NR1H4 (0.46) LRRK2NR1H4ALDH1A1FFAR4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300973-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO. LTD. (CN) 2024-09-12 US disclosed
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-04-04 US disclosed
CN-117157296-A Modulators of FPR1 and methods of use thereof 首都医科大学附属北京天坛医院 2023-12-01 CN disclosed
EP-4281453-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2023-11-29 EP disclosed
EP-4281452-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME Beijing Tiantan Hospital (CN) 2023-11-29 EP disclosed
CN-114805387-A Modulators of FPR1 and methods of use thereof 百放英库医药科技(北京)有限公司 2022-07-29 CN disclosed
WO-2022155860-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2022-07-28 WO disclosed
WO-2022155859-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BEIJING TIANTAN HOSPITAL (CN) 2022-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300973-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME FPR1, FPR2, FPR3 LRRK2 2910/4885PTGER1 13/4885PTGER4 153/4885
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME FPR1, FPR2, FPR3 LRRK2 2910/4885PTGER1 13/4885PTGER4 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.